Neoadjuvant therapy in early-stage breast cancer

Critical Reviews in Oncology/Hematology

Volumn 82, Issue 2, 2012, Pages 187-199

  Moreno Aspitia, Alvaro ^a  

^a MAYO CLINIC   (United States)

Author keywords

Breast cancer; Early stage; Neoadjuvant; Pathologic response

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROURACIL; GEFITINIB; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IXABEPILONE; LAPATINIB; METHOTREXATE; NAVELBINE; PACLITAXEL; PERTUZUMAB; PROGESTERONE RECEPTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SUNITINIB; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; UNINDEXED DRUG;

ADJUVANT THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER STAGING; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; DIARRHEA; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG RESPONSE; EARLY CANCER; HAND FOOT SYNDROME; HEARING LOSS; HUMAN; HYPERTENSION; INFECTION; LOADING DRUG DOSE; LUNG EMBOLISM; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NEUROPATHY; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PATIENT COMPLIANCE; PREOPERATIVE CARE; RECURRENCE FREE SURVIVAL; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOPHLEBITIS; TINNITUS; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; TUMOR MARKERS, BIOLOGICAL;

EID: 84859431805     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2011.04.013     Document Type: Review

References (90)

1. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. V.1.2009. http://www.nccn.org/.
2. Fisher B., Anderson S., Bryant J., et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002, 347:1233-1241.
3. Fisher B., Jeong J.H., Anderson S., Bryant J., Fisher E.R., Wolmark N.L. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002, 347:567-575.
4. Veronesi U., Cascinelli N., Mariani L., et al. Twenty-year follow-up of a randomized study comparing breast conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002, 347:1227-1232.
5. Mauri D., Pavlidis N., Ioannidis J.P. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005, 97:188-194.
6. Oh J.L., Nguyen G., Whitman G.J., et al. Placement of radiopaque clips for tumor localization in patients undergoing neoadjuvant chemotherapy and breast conservation therapy. Cancer 2007, 110:2420-2427.
7. De Lena M., Zucali R., Viganotti G., Valagussa P., Bonadonna G. Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother Pharmacol 1978, 1:53-59.
8. Fisher B., Brown A., Mamounas E., et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997, 15:2483-2493.
9. Rastogi P., Anderson S.J., Bear H.D., et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008, 26:778-785.
10. Mieog J.S., van der Hage J.A., van de Velde C.J. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev 2007, (2). Art.No.:CD005002. http://www2.cochrane.org/reviews/en/ab005002.html. 10.1002/14651858.CD005002.pub2.
11. Smith I.E., A'Hern R.P., Coombes G.A., et al. A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. Ann Oncol 2004, 15:751-758.
12. Green M.C., Buzdar A.U., Smith T., et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 2005, 23:5983-5992.
13. Evans T.R., Yellowlees A., Foster E., et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an Anglo-Celtic Cooperative Oncology Group Study. J Clin Oncol 2005, 23:2988-2995.
14. von Minckwitz G., Raab G., Caputo A., et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 2005, 23:2676-2685.
15. Bear H.D., Anderson S., Smith R.E., et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006, 24:2019-2027.
16. Vriens BE, Van de Vijver KK, Boetes C, van Gastel SM, Wals J, Smilde TJ. Sequential versus upfront intensified neoadjuvant chemotherapy in patients with large resectable or locally advanced breast cancer (INTENS), first results from a phase III study of the Dutch Breast Cancer Trialist's Group (BOOG). Presented at the 33rd annual San Antonio breast cancer symposium; 2010 (abstract P1-11-10).
17. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, Aura C, De Azambuja E. First results of the NeoALTTO trial (BIG 01-06/EGF 106903): a phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer. Presented at the 33rd annual San Antonio breast cancer symposium; 2010 (abstract S3-3).
18. Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer J-U. Lapayinib vs trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy: primary efficacy endpoint analysis of the GEPARQUINTO STUDY (GBG 44). Presented at the 33rd annual San Antonio breast cancer symposium; 2010 (abstract S3-1).
19. von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H. Neoadjuvant Chemotherapy with or without Bevacizumab: Primary Efficacy Endpoint Analysis of the GEPARQUINTO Study (GBG 44). Presented at the 33rd annual San Antonio breast cancer symposium; 2010 (abstract S4-6).
20. Gianni L., Baselga J., Eiermann W., et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. J Clin Oncol 2009, 27:2474-2481.
21. Sparano J.A., Wang M., Martino S., et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008, 358:1663-1671.
22. Citron M.L., Berry D.A., Cirrincione C., et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003, 21:1431-1439.
23. Albain K.S., Green S.J., Ravdin P.M., et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from Intergroup trial 0100 (SWOG-8814). J Clin Oncol 2002, 21:37a. (abstract 143).
24. von Minckwitz G., Kümmel S., Vogel P., et al. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst 2008, 100:552-562.
25. von Minckwitz G., Rezai M., Loibl S., et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol 2010, 28:2015-2023.
26. Culine S., Romieu G., Fabbro M., et al. Reducing the time interval between cycles using standard doses of docetaxel and lenogastrim support: a feasibility study. Cancer 2004, 101:178-182.
27. Mitchell P.L., Basser R., Chipman M., et al. A phase II study of escalated-dose docetaxel with granulocyte colony-stimulating factor support in patients with advanced breast cancer. Ann Oncol 2004, 15:585-589.
28. Paciucci P.A., Raptis G., Bleiweiss I., Weltz C., Lehrer D., Gurry R. Neo-adjuvant therapy with dose-dense docetaxel plus short-term filgrastim rescue for locally advanced breast cancer. Anticancer Drugs 2002, 13:791-795.
29. Jacot W., Bibeau F., Gourgou-Bourgade S., et al. Phase II trial of dose dense docetaxel followed by FEC100 as neoadjuvant chemotherapy in patients with operable breast cancer. Am J Clin Oncol 2010, 33:544-549.
30. Kaufmann M., von Minckwitz G., Bear H.D., et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 2007, 18:1927-1934.
31. Colleoni M., Gelber S., Coates A.S., et al. Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. J Clin Oncol 2001, 19:4141-4149.
32. Gianni L., Baselga J., Eiermann W., et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res 2005, 11:8715-8721.
33. Dent R., Trudeau M., Pritchard K.I., et al. Triple negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007, 13:4429-4434.
34. Carey L.A., Dees E.C., Sawyer L., et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007, 13:2329-2334.
35. Haffty B.G., Yang Q., Reiss M., et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006, 24:5652-5657.
36. Kim K.I., Lee E.S., Lee J.-A., Bae J.W. Clinicopathologic signature of TNBC patients with good prognosis. Cancer Res 2009, 69(24 Suppl.):728s. (abstract 4065).
37. Guiu S., Arnould L., Coudert B., et al. Neoadjuvant chemotherapy for triple-negative breast cancer: pathologic complete response and survival after long-term follow-up. Cancer Res 2009, 69(24 Suppl.):572s. (abstract 1103).
38. Ring A.E., Smith I.E., Ashley S., Fulford L.G., Lakhani S.R. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer 2004, 91:2012-2017.
39. Colleoni M., Viale G., Zarieh D., et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 2004, 10:6622-6628.
40. Hennessy B.T., Hortobagyi G.N., Rouzier R., et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 2005, 23:9304-9311.
41. Liedtke C., Mazouni C., Hess K.R., et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008, 26:1275-1281.
42. Rody A., Karn T., Gätje R., et al. Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response. Breast 2007, 16:86-93.
43. Loibl S., Blohmer J.U., Raab G., et al. Prospective central assessment of HER-2 status by FISH is not a predictive factor for pathologic complete response (pCR) in 648 breast cancer patients treated preoperatively with an anthracycline/taxane based regimen in the multicenter GeparTrio trial. Breast Cancer Res Treat 2005, 94:S46. (abstract 1023).
44. Bozzetti C., Musolino A., Camisa R., et al. Evaluation of Her-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity. Am J Clin Oncol 2006, 29:171-177.
45. Darb-Esfahani S., Loibl S., Muller B.M., et al. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer Res 2009, 11:R69.
46. Guarneri V., Broglio K., Kau S.W., et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006, 24:1037-1044.
47. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
48. Nielsen T.O., Jewell S.D., Thor A.D., et al. Intrinsic subtype and response to paclitaxel in CALGB 9344 tissue microarrays. ASCO Breast Cancer Symposium 2009, (abstract 23).
49. Parker J.S., Mullins M., Cheang M.C., et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009, 27:1160-1167.
50. Parker J.S., Prat A., Cheang M.C.U., Lenburg M.E., Paik S., Perou C.M. Breast cancer molecular subtypes predict response to anthracycline/taxane-based chemotherapy. Cancer Res 2009, 69(24 Suppl.):598s. (abstract 2019).
51. Budzar A.U., Valero V., Ibrahim N.K., et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2 - positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007, 13:228-233.
52. Sikov W.M., Dizon D.S., Strenger R., et al. Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group study. J Clin Oncol 2009, 27:4693-4700.
53. Gianni L., Eiermann W., Semiglazov V., et al. Neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer: primary efficacy analysis of the NOAH trial. Cancer Res 2009, 69(2 Suppl.). (abstract 31).
54. Untch M., Rezai M., Loibl S., et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro Study. J Clin Oncol 2010, 28:2024-2031.
55. Mathew J., Asgeirsson K.S., Jackson L.R., Cheung K.L., Robertson J.F. Neoadjuvant endocrine treatment in primary breast cancer - review of literature. Breast 2009, 18:339-344.
56. Miller W.R., White S., Dixon J.M., Murray J., Renshaw L., Anderson T.J. Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole. Br J Cancer 2006, 94:1051-1056.
57. Ellis M.J., Tao Y., Luo J., et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 2008, 100:1380-1388.
58. Dowsett M., Ebbs S.R., Dixon J.M., et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer: a study from the IMPACT trialists. J Clin Oncol 2005, 23:2477-2492.
59. Dowsett M., Smith I.E., Ebbs S.R., et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 2005, 11:951s-958s.
60. Anderson H., Bulun S., Smith I., Dowsett M. Predictors of response to aromatase inhibitors. J Steroid Biochem Mol Biol 2007, 106(1-5):49-54.
61. Dowsett M., Smith I.E., Ebbs S.R., et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007, 99:167-170.
62. Tan S.M., Cheung K.L., Willsher P.C., Blamey R.W., Chan S.Y., Robertson J.F. Locally advanced primary breast tumour: medium-term results of a randomized controlled trial of multimodal therapy versus initial hormone therapy. Eur J Cancer 2001, 37:2331-2338.
63. Robertson J.F., Ellis I.O., Elston C.W., Blamey R.W. Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-year follow-up. Eur J Cancer 1992, 28A(4-5):908-910.
64. Mustacchi G., Ceccherini R., Milani S., et al. Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. Ann Oncol 2003, 14:414-420.
65. Eiermann W., Paepke S., Appfelstaedt J., et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomised double-blind multicenter study. Ann Oncol 2001, 12:1527-1532.
66. Ellis M.J., Coop A., Singh B., et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001, 19:3808-3816.
67. Semiglazov V., Semiglazov V.V., Ivanov V.G., et al. Anastrazole vs tamoxifen vs combination as neoadjuvant endocrine therapy of postmenopausal breast cancer patients. J Clin Oncol 2003, 22:880. (abstract 3538).
68. Smith I.E., Dowsett M., Ebbs S.R., et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005, 23:5108-5116.
69. Dixon J.M., Jackson J., Renshaw L., Miller W.R. Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes. J Steroid Biochem Mol Bio 2003, 86:295-299.
70. Anderson T.J., Dixon J.M., Stuart M., Sahmoud T., Miller W.R. Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer. Br J Cancer 2002, 87:334-338.
71. Miller W.R., Dixon J.M., Macfarlane L., Cameron D., Anderson T.J. Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen. Eur J Cancer 2003, 39:462-468.
72. Semiglazov V.F., Semiglazov V.V., Dashyan G.A., et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer 2007, 110:244-254.
73. Cristofanilli M., Gonzalez-Angulo A., Sneige N., et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 2005, 23:41-48.
74. Krainick-Strobel U.E., Lichtenegger W., Wallwiener D., et al. Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy. BMC Cancer 2008, 8:62.
75. Dixon J.M., Renshaw L., Macaskill E.J., et al. Increase in response rate by prolonged treatment with neoadjuvant letrozole. Breast Cancer Res Treat 2009, 113:145-151.
76. Mathew J., Agrawal A., Asgerisson K., et al. Primary endocrine therapy in locally advanced breast cancers - Nottingham experience. Breast Cancer Res Treat 2009, 113:403-407.
77. Steger G.G., Greil R., Jakesz R., et al. Final results of ABCSG-24, a randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer and comparing ED/EDC+trastuzumab (T) to ED/EDC as neoadjuvant treatment for early HER-2 positive breast cancer. Cancer Res 2009, 69(24 Suppl.):564s. (abstract 1081).
78. Earl H.M., Vallier A., Hiller L., et al. Neo-tAnGo: a neoadjuvant randomized phase III trial of epirubicin/cyclophosphamide and paclitaxel±gemcitabine in the treatment of women with high-risk early breast cancer (EBC): first report of the primary endpoint, pathological complete response (pCR). J Clin Oncol 2009, 27:15s. (abstract 522).
79. Poole C.J., Hiller L., Howard H.C., et al. tAnGo: a randomized phase III trial of gemcitabine (gem) in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy (CT) for women with early-stage breast cancer (EBC). J Clin Oncol 2008, 26(Suppl.):8s. (abstract 506).
80. Chua S., Smith I.E., A'Hern R.P., et al. Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2). Ann Oncol 2005, 16:1435-1441.
81. Vahdat L. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms. Oncologist 2008, 13:214-221.
82. Rugo H.S., Campone M., Amadori D., et al. Randomized phase II study of weekly versus every-3-week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC). J Clin Oncol 2009, 27(Suppl.):47s. (abstract 1029).
83. Baselga J., Zambetti M., Llombart-Cussac A., et al. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. J Clin Oncol 2009, 27:526-534.
84. Horak C.E., Lee F.Y., Xu L., Galbraith S., Baselga J. High β-III tubulin expression in triple-negative (TN) breast cancer (BC) subtype and correlation to ixabepilone response: a retrospective analysis. J Clin Oncol 2009, 27:15s. (abstract 3587).
85. Dumontet C., Jordan M.A., Lee F.F. Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies. Mol Cancer Ther 2009, 8:17-25.
86. Arpino G., Green S.J., Allred D.C., et al. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res 2004, 10:5670-5676.
87. Gianni L, Pienkowski T, Im Y-H, Roman L, Tseng L-M, Liu M-C. Neoadjuvant pertuzumab (P) and trastuzumab (H): antitumor and safety analysis of a randomized phase II study ('NeoSphere'). Presented at the 33rd annual San Antonio breast cancer symposium; 2010 (abstract S3-2).
88. Polychronis A., Sinnett H.D., Hadjiminas D., et al. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. Lancet Oncol 2005, 6:383-391.
89. Smith I.E., Walsh G., Skene A., et al. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol 2007, 25:3816-3822.
90. Ryan P.D., Tung N.M., Isakoff S.J., et al. Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): safety and efficacy. J Clin Oncol 2009, 27(Suppl.):18s. (abstract 551).